# Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

> **NCT01304160** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer
- Unresectable Pancreatic Cancer

## Interventions

- **RADIATION:** stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT01304160
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01304160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01304160, "Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01304160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*